Emily B Schroeder1,2, Xiuhai Yang3, Micah L Thorp4, Brent M Arnold5, David C Tabano6, Amanda F Petrik3, David H Smith3, Robert W Platt7, Eric S Johnson3. 1. Institute for Health Research and Emily.x.schroeder@kp.org. 2. Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. 3. Center for Health Research and. 4. Department of Nephrology, Kaiser Permanente Northwest, Portland, Oregon; and. 5. Department of Nephrology, Kaiser Permanente Colorado, Denver, Colorado. 6. Institute for Health Research and. 7. Department of Epidemiology, Biostatistics and Occupational Health, McGill University Health Centre Research Institute, Montreal, Quebec, Canada.
Abstract
BACKGROUND AND OBJECTIVES: Only a minority of patients with CKD progress to renal failure. Despite the potential benefits of risk stratification in the CKD population, risk prediction models are not routinely used. Our objective was to develop and externally validate a clinically useful and pragmatic prediction model for the 5-year risk of progression to RRT in stage 3 or 4 CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used a retrospective cohort design. The development cohort consisted of 22,460 Kaiser Permanente Northwest members with stage 3 or 4 CKD (baseline 2002-2008). The validation cohort consisted of 16,553 Kaiser Permanente Colorado members with stage 3-4 CKD (baseline 2006-2008). The final model included eight predictors: age, sex, eGFR, hemoglobin, proteinuria/albuminuria, systolic BP, antihypertensive medication use, and diabetes and its complications. RESULTS: In the Northwest and Colorado cohorts, there were 737 and 360 events, and observed 5-year Kaplan-Meier risks of 4.72% (95% confidence interval [95% CI], 4.38 to 5.06) and 2.57% (95% CI, 2.30 to 2.83), respectively. Our prediction model performed extremely well in the development cohort, with a c-statistic of 0.96, an R2 of 79.7%, and good calibration. We had similarly good performance in the external validation cohort, with a c-statistic of 0.95, R2 of 81.2%, and good calibration. In the external validation cohort, the observed risk was slightly lower than the predicted risk in the highest-risk quintile. Using the top quintile of predicted risk as a cutpoint gave a sensitivity of 92.2%. CONCLUSIONS: We developed a pragmatic prediction model and risk score for predicting the 5-year RRT risk in stage 3 and 4 CKD. This model uses variables that are typically available in routine primary care settings, and can be used to help guide important decisions such as timing of referral to nephrology and fistula placement.
BACKGROUND AND OBJECTIVES: Only a minority of patients with CKD progress to renal failure. Despite the potential benefits of risk stratification in the CKD population, risk prediction models are not routinely used. Our objective was to develop and externally validate a clinically useful and pragmatic prediction model for the 5-year risk of progression to RRT in stage 3 or 4 CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used a retrospective cohort design. The development cohort consisted of 22,460 Kaiser Permanente Northwest members with stage 3 or 4 CKD (baseline 2002-2008). The validation cohort consisted of 16,553 Kaiser Permanente Colorado members with stage 3-4 CKD (baseline 2006-2008). The final model included eight predictors: age, sex, eGFR, hemoglobin, proteinuria/albuminuria, systolic BP, antihypertensive medication use, and diabetes and its complications. RESULTS: In the Northwest and Colorado cohorts, there were 737 and 360 events, and observed 5-year Kaplan-Meier risks of 4.72% (95% confidence interval [95% CI], 4.38 to 5.06) and 2.57% (95% CI, 2.30 to 2.83), respectively. Our prediction model performed extremely well in the development cohort, with a c-statistic of 0.96, an R2 of 79.7%, and good calibration. We had similarly good performance in the external validation cohort, with a c-statistic of 0.95, R2 of 81.2%, and good calibration. In the external validation cohort, the observed risk was slightly lower than the predicted risk in the highest-risk quintile. Using the top quintile of predicted risk as a cutpoint gave a sensitivity of 92.2%. CONCLUSIONS: We developed a pragmatic prediction model and risk score for predicting the 5-year RRT risk in stage 3 and 4 CKD. This model uses variables that are typically available in routine primary care settings, and can be used to help guide important decisions such as timing of referral to nephrology and fistula placement.
Authors: Ron T Gansevoort; Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh Journal: Kidney Int Date: 2011-02-02 Impact factor: 10.612
Authors: Navdeep Tangri; Morgan E Grams; Andrew S Levey; Josef Coresh; Lawrence J Appel; Brad C Astor; Gabriel Chodick; Allan J Collins; Ognjenka Djurdjev; C Raina Elley; Marie Evans; Amit X Garg; Stein I Hallan; Lesley A Inker; Sadayoshi Ito; Sun Ha Jee; Csaba P Kovesdy; Florian Kronenberg; Hiddo J Lambers Heerspink; Angharad Marks; Girish N Nadkarni; Sankar D Navaneethan; Robert G Nelson; Stephanie Titze; Mark J Sarnak; Benedicte Stengel; Mark Woodward; Kunitoshi Iseki Journal: JAMA Date: 2016-01-12 Impact factor: 56.272
Authors: Ewout W Steyerberg; Andrew J Vickers; Nancy R Cook; Thomas Gerds; Mithat Gonen; Nancy Obuchowski; Michael J Pencina; Michael W Kattan Journal: Epidemiology Date: 2010-01 Impact factor: 4.822
Authors: Bessie Ann Young; Elizabeth Lin; Michael Von Korff; Greg Simon; Paul Ciechanowski; Evette J Ludman; Siobhan Everson-Stewart; Leslie Kinder; Malia Oliver; Edward J Boyko; Wayne J Katon Journal: Am J Manag Care Date: 2008-01 Impact factor: 2.229
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Robert G Weaver; Matthew T James; Pietro Ravani; Colin G W Weaver; Edmund J Lamb; Marcello Tonelli; Braden J Manns; Robert R Quinn; Min Jun; Brenda R Hemmelgarn Journal: J Am Soc Nephrol Date: 2020-02-05 Impact factor: 10.121
Authors: Noel Engels; Gretchen N de Graav; Paul van der Nat; Marinus van den Dorpel; Anne M Stiggelbout; Willem Jan Bos Journal: BMJ Open Date: 2022-09-21 Impact factor: 3.006
Authors: Pottumarthi V Prasad; Lu-Ping Li; Jon M Thacker; Wei Li; Bradley Hack; Orly Kohn; Stuart M Sprague Journal: Am J Nephrol Date: 2019-01-22 Impact factor: 3.754
Authors: Chava L Ramspek; Marie Evans; Christoph Wanner; Christiane Drechsler; Nicholas C Chesnaye; Maciej Szymczak; Magdalena Krajewska; Claudia Torino; Gaetana Porto; Samantha Hayward; Fergus Caskey; Friedo W Dekker; Kitty J Jager; Merel van Diepen Journal: J Am Soc Nephrol Date: 2021-03-08 Impact factor: 10.121